Table 1.
Clinicopathological characteristics of patients with stage II/III gastric cancer n (%)
| Characteristic | Surgery alone | Surgery + chemotherapy | P value |
| No. of patients | 117 | 169 | |
| Age (yr) | |||
| Median (range) | 62 (31-80) | 58 (25-80) | 0.063 |
| < 70 | 89 (76.1) | 142 (84.0) | 0.093 |
| ≥ 70 | 28 (23.9) | 27 (16.0) | |
| Sex, n | 0.924 | ||
| Men | 83 (70.9) | 119 (70.4) | |
| Women | 34 (29.1) | 50 (20.6) | |
| Karnofsky performance status | 0.515 | ||
| ≥ 90 | 116 (99.1) | 166 ( 98.2) | |
| ≥ 80 | 1(0.9) | 3 (1.8) | |
| Tumor location | 0.054 | ||
| Proximal | 77 (65.8) | 92 (54.4) | |
| Distal | 40 (34.2) | 77 (45.6) | |
| Histological grade | 0.120 | ||
| High differentiation | 0 (0.0) | 4 (2.4) | |
| Moderate differentiation | 32 (27.4) | 35 (20.7) | |
| Low differentiation | 85 (72.6) | 130 (76.9) | |
| Gloss type | 0.429 | ||
| Protrusion | 41 (35.0) | 64 (37.9) | |
| Ulcer | 71 (60.7) | 102 (60.4) | |
| Infiltration | 5 (4.3) | 3 (1.8) | |
| Tumor size | 0.359 | ||
| < 5 cm | 41 (35.3) | 51 (30.2) | |
| ≥ 5 cm | 75 (64.7) | 118 (60.8) | |
| Preoperative serum CEA | 0.207 | ||
| Median (range) | 2.42 (0.2–326.8) | 2.235 (0.2–265.5) | |
| Preoperative serum CA19-9 | 0.729 | ||
| Median (range) | 11.33 (0.6–206.9) | 10.83 (0.6–3098.0) | |
| CEA tumor status | 0.792 | ||
| – | 12 (10.3) | 19 (11.2) | |
| + | 105 (89.7) | 150 (88.8) | |
| P53 tumor status | 0.813 | ||
| – | 27 (23.1) | 37 (21.9) | |
| + | 90 (76.9) | 132 (78.1) | |
| T category | 0.182 | ||
| T1 | 0 (0.0) | 2 (1.2) | |
| T2 | 7 (6.0) | 20 (11.8) | |
| T3 | 91 (77.8) | 116 (68.6) | |
| T4 | 19 (12.6) | 31 (18.3) | |
| N category | 0.069 | ||
| N0 | 31 (26.5) | 37 (21.9) | |
| N1 | 19 (16.2) | 29 (17.2) | |
| N2 | 33 (28.2) | 31 (18.3) | |
| N3 | 34 (29.1) | 72 (42.6) | |
| AJCC stage (7th) | 0.066 | ||
| IIA | 29 (24.8) | 38 (22.5) | |
| IIB | 11 (9.4) | 26 (15.4) | |
| IIIA | 34 (29.1) | 34 (20.1) | |
| IIIB | 40 (34.2) | 56 (33.1) | |
| IIIC | 3 (2.6) | 15 (8.9) | |
CEA: Carcinoembryonic antigen.